Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kisspeptin and Glucose-Stimulated Insulin Secretion
NCT04958109Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of kisspeptin, sponsored by Massachusetts General Hospital. Primary endpoint: Oral Glucose Sensitivity Index at 3 hours. Started Oct 2021; status: completed.
02
Drugs
kisspeptin
Beyond the preview
Go deeper on NCT04958109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958109.